doi: 10.1007/BF03190054.
Differences in reference products: dissolution and in vivo evidence
Affiliations
- PMID: 11032087
- DOI: 10.1007/BF03190054
Item in Clipboard
Differences in reference products: dissolution and in vivo evidence
Eur J Drug Metab Pharmacokinet.
2000 Jan-Mar.
No abstract available
Similar articles
-
United States Food and Drug Administration requirements for approval of generic drug products.J Clin Psychiatry. 2001;62 Suppl 5:4-9; discussion 23-4. J Clin Psychiatry. 2001. PMID: 11305846 Review.
-
Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.J Pharm Pharmacol. 2006 Nov;58(11):1475-82. doi: 10.1211/jpp.58.11.0008. J Pharm Pharmacol. 2006. PMID: 17132210 Clinical Trial.
-
Generic drug product equivalence: current status.Am J Manag Care. 1998 Aug;4(8):1183-9; quiz 1190-2. Am J Manag Care. 1998. PMID: 10182892
-
Progress and Hurdles for Follow-on Biologics.N Engl J Med. 2015 Jun 18;372(25):2380-2. doi: 10.1056/NEJMp1504672. Epub 2015 May 6. N Engl J Med. 2015. PMID: 25946143 No abstract available.
-
Generic drug device combination products: Regulatory and scientific considerations.Int J Pharm. 2018 Jun 15;544(2):443-454. doi: 10.1016/j.ijpharm.2017.11.038. Epub 2017 Nov 21. Int J Pharm. 2018. PMID: 29170118 Review.